Pseudomonas deficient in protease IV has significantly reduced corneal virulence

Investigative Ophthalmology and Visual Science

Volumn 38, Issue 8, 1997, Pages 1535-1542

  Engel, Lee S ^a   Hobden, Jeffrey A ^a   Moreau, Judy M ^a   Callegan, Michelle C ^a   Hill, James M ^a   O'Callaghan, Richard J ^a  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

Animal model; Keratitis; Protease IV; Pseudomonas; Virulence

Indexed keywords

PROTEASE IV; PROTEINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BACTERIAL MUTATION; BACTERIAL VIRULENCE; ENZYME ANALYSIS; FEMALE; KERATITIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RABBIT; STRAIN DIFFERENCE;

ANIMALS; COLONY COUNT, MICROBIAL; CORNEA; CORNEAL DISEASES; CORNEAL STROMA; FEMALE; MICE; PEPTIDE HYDROLASES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RABBITS; SPECIES SPECIFICITY;

EID: 0030739710     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. O'Callaghan RJ, Engel LS, Hobden JA, Callegan MC, Green LC, Hill JM. The role of an uncharacterized exoprotein, protease IV, in corneal virulence. Invest Ophthalmol Vis Sci. 1996;37:534-543.
2. Nicas TI, Iglewski BH. The contribution of exoproducts to virulence of Pseudomonas aeruginosa. Can J Microbiol. 1985;31:387-392.
3. Liesegang TJ. Bacterial and fungal keratitis. In: Kaufman HE, Barron BA, McDonald MB, Waltman SR, eds. The Cornea. New York: Churchill Livingstone; 1988: 217-270.
4. Howe TR, Iglewski BH. Isolation and characterization of alkaline protease-deficient mutants of Pseudomonas in vitro and in a mouse eye model. Infect Immun 1984;43:1058-1063.
5. Arffa RC. Infectious ulcerative keratitis: Bacterial. In: Grayson's Diseases of the Cornea. St. Louis: Mosby-Year Book; 1991:163-198.
6. Holland SP, Pulido JS, Shires TK, Costerton JW. Pseudomonas aeruginosa ocular infections. In: Fich RB, ed. Pseudomonas aeruginosa the Opportunist: Pathogenesis and Disease. Boca Raton, FL: CRC Press; 1993:159-176.
7. Iglewski BH. Probing Pseudomonas aeruginosa, an opportunistic pathogen. ASM News. 1989;55:303-307.
8. Barza M. Antibacterial agents in the treatment of ocular infections. Infect Dis Clin North Am. 1989;3:533-551.
9. Ohman DE, Sadoff JC, Iglewski BH. Toxin A-deficient mutants of Pseudomonas aeruginosa PA103: Isolation and characterization. Infect Immun. 1980;28:899-908.
10. Gambello MJ, Iglewski BH. Cloning and characterization of the Pseudomonas aeruginosa lasR. gene, a transcriptional activator of elastase expression. J Bacteriol. 1991;173:3000-3009.
11. Saiman L, Ishimoto K, Lory S, Prince A. The effect of piliation and exoproduct expression on the adherence of Pseudomonas aeruginosa to respiratory epithelial monolayers. J Infect Dis. 1989;161:541-548.
12. Wretlind B, Sjoberg L, Wadstrom T. Protease-deficient mutants of Pseudomonas aeruginosa: Pleiotropic changes in activity of other extracellular enzymes. J Gen Microbiol. 1977;103:329-336.
13. Chung DW, Collier RJ. Enzymatically active peptide from the adenosine diphosphate-ribosylating toxin of Pseudomonas aeruginosa. Infect Immun. 1977;16:832-841.
14. Nicas TI, Iglewski BH. Contribution of exoenzyme S to the virulence of Pseudomonas aeruginosa. Antibiot Chemother. 1985;36:40-48.
15. Twining SS, Davis SD, Hyndiuk RA. Relationship between proteases and descemetocele formation in experimental Pseudomonas keratitis. Curr Eyes Res. 1986; 5:503-510.
16. Herron GS, Banda MJ, Clark EJ, Gavrilovic J, Werb Z. Secretion of metalloproteinases by stimulated capillary endothelial cells II: Expression of collagenase and stromelysin activities is regulated by endogenous inhibitors. J Biol Chem. 1986;261:2814-2818.
17. Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activators in polyacrylamide gel containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem. 1980;102:196-202.
18. Hobden JA, Reidy JJ, O'Callaghan RJ, Hill JM. Ciprofloxacin iontophoresis for aminoglycoside-resistant pseudomonal keratitis. Invest Ophthalmol Vis Sci. 1990;31:1940-1944.
19. Hobden JA, Reidy JJ, O'Callaghan RJ, Insler MS, Hill JM. Quinolones in collagen shields to treat aminogly-coside-resistant pseudomonal keratitis. Invest Ophthalmol Vis Sci. 1990;31:2241-2243.
20. Hobden JA, Rootman DS, O'Callaghan RJ, Hill JM. Iontophoretic application of tobramycin to uninfected and Pseudomonas aeruginosa-infected rabbit corneas. Antimicrob Agents Chemother. 1988;32:978-981.
21. Rootman DS, Hobden JA, Jantzen JA, Gonzalez VR, O'Callaghan RJ, Hill JM. Iontophoresis of tobramycin for the treatment of experimental Pseudomonas keratitis in the rabbit. Arch Ophthalmol. 1988;106:262-265.
22. Brockman EB, Tarantino PA, Hobden JA, et al. Keratotomy model of Pseudomonas aeruginosa keratitis: Gentamicin chemotherapy. Refract Corneal Surg. 1992; 8:39-43.
23. Hobden JA, Engel LS, Callegan MC, Hill JM, Gebhardt BM, O'Callaghan RJ. Pseudomonas aeruginosa keratitis in leukopenic rabbits. Curr Eye Res. 1993;12:1461-467.
24. Hobden JA, Engel LS, Hill JM, Callegan MC, O'Callaghan RJ. Prednisolone acetate or prednisolone phosphate concurrently administered with ciprofloxacin for the therapy of experimental Pseudomonas aeruginosa keratitis. Curr Eye Res. 1993;12:469-473.
25. Hobden JA, O'Callaghan RJ, Hill JM, Reidy JJ, Rootman DS, Thompson HW. Tobramycin iontophoresis into corneas infected with drug resistant Pseudomonas aeruginosa. Curr Eye Res. 1989;8:1163-1169.
26. Hobden JA, O'Callaghan RJ, Hill JM, Hagenah M, Insler MS, Reidy JJ. Ciprofloxacin and prednisolone therapy for experimental Pseudomonas keratitis. Curr Eye Res. 1992;11:259-266.
27. Gerke JR, Magliocco MV. Experimental Pseudomonas aeruginosa infections of the mouse cornea. Infect Immun. 1971;3:209-216.
28. SAS Institute, Inc. SAS Users Guide: Statistics. Version 5. Gary NC: SAS Institute; 1985.
29. Gambello MJ, Kaye S, Iglewski BH. LasR of Pseudomonas aeruginosa is a transcriptional activator of the alkaline protease gene (apr) and an enhancer of exotoxin A expression. Infect Immun. 1993;61;1180-1184.
30. Hazlett LD, Masinick S, Barrett R, Rosol K. Evidence for asialo GM1 as a corneal glycolipid receptor for Pseudomonas aeruginosa adhesion. Infect Immun. 1993; 61:5164-5173.
31. Hong YQ, Ghebrehiwet B. Effect of Pseudomonas aeruginosa elastase and alkaline protease on serum complement and isolated components C1q and C3. Immunol Immunopathol. 1992;62:133-138.
32. Parmely M, Gale A, Clabaugh M, Horvat R, Zhou WW. Proteolytic inactivation of cytokines by Pseudomonas aeruginosa. Infect Immun. 1990;58:3009-3014.
33. Horvat RT, Parmely MJ. Pseudomonas aeruginosa alkaline protease degrades human gamma interferon and inhibits its bioactivity. Infect Immun. 1988;56:2925-2932.
34. Heck LW, Macron PG, Kulhavy RM, Morihara K, Russel MW, Mestecky JF. Degradation of IgA proteins by Pseudomonas aeruginosa elastase. J. Immunol. 1990; 144:2253-2257.
35. Kharazmi A. Mechanisms involved in the erosion of the host defense by Pseudomonas aeruginosa. Immunol Lett. 1991;30:201-206.
36. Matsumoto K, Shams NBK, Hanninen LA, Kenyon KR. Proteolytic activation of corneal matrix metalloproteinase by Pseudomonas aeruginosa elastase. Curr Eye Res. 1992;11:1105-1109.
37. Twining SS, Kirschner SA, Mahnke LA, Frank DW. Effect of Pseudomonas aeruginosa elastase, alkaline protease and exotoxin A on corneal proteases and proteins. Invest Ophthalmol Vis Sci. 1993;34:2699-2712.
38. Toder SD, Gambello MJ. Pseudomonas aeruginosa protease IV: Cloning of caseinase which is not transcriptionally activated by lasR. Presented at the 92nd General Meeting of the American Society for Microbiology; May 28, 1992.